Inhibrx granted fast track designation for INBRX-109 for the treatment of unresectable or metastatic conventional chondrosarcoma patients

Inhibrx

13 January 2020 - Registration enabling study expected to begin dosing in the second or third quarter of this year.

Inhibrx announced today the U.S. FDA granted fast track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. 

INBRX-109 is a precisely engineered tetravalent single domain antibody based therapeutic candidate that agonises death receptor 5 to induce tumour selective programmed cell death.

Read Inhibrx press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track